Novus Therapeutics, Inc. (NVUS)’s Trend Up, Especially After Today’s Strong Session

March 14, 2018 - By Adrian Mccoy

The stock of Novus Therapeutics, Inc. (NASDAQ:NVUS) is a huge mover today! The stock increased 23.82% or $1.11 during the last trading session, reaching $5.77. About 216,008 shares traded or 331.99% up from the average. Novus Therapeutics, Inc. (NASDAQ:NVUS) has 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.
The move comes after 9 months positive chart setup for the $40.88M company. It was reported on Mar, 14 by We have $6.23 PT which if reached, will make NASDAQ:NVUS worth $3.27M more.

More notable recent Novus Therapeutics, Inc. (NASDAQ:NVUS) news were published by: which released: “BRIEF-Andrew I. Mcdonald Reports 12.24 pct Passive Stake In Novus Therapeutics …” on March 13, 2018, also with their article: “Otic Pharma Completes Merger with Tokai Pharmaceuticals” published on May 10, 2017, published: “Novus Therapeutics Announces the Promotion of Dr. Catherine Turkel to President” on November 06, 2017. More interesting news about Novus Therapeutics, Inc. (NASDAQ:NVUS) were released by: and their article: “Novus Therapeutics Announces Change in Management” published on July 10, 2017 as well as‘s news article titled: “Novus Therapeutics Inc.” with publication date: June 12, 2017.

Novus Therapeutics, Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of ear, nose, and throat products. The company has market cap of $40.88 million. The Company’s lead product is a nasally-administered combination drug product intended to address the underlying cause of otitis media and Eustachian tube dysfunction (OM/ETD) conditions. It currently has negative earnings. The firm also has a foam drug delivery technology platform (OP-01) that could be used to deliver drugs into the ear, nose, and sinus cavities.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: